Marc Lafrance

Title: The Innovative Contributions of Marc Lafrance

Introduction

Marc Lafrance is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the area of cell proliferation disorders. His work focuses on developing innovative solutions that can improve treatment options for patients suffering from these conditions.

Latest Patents

Marc Lafrance holds a patent for "Cell proliferation inhibitors and conjugates thereof." This patent discloses immunoconjugates that comprise an inhibitor of Eg5 linked to an antigen binding moiety, such as an antibody. These immunoconjugates are useful for treating cell proliferative disorders. The invention also includes novel inhibitors of Eg5 that can be utilized either alone or as part of an immunoconjugate. Furthermore, the patent provides pharmaceutical compositions that comprise these compounds and immunoconjugates, along with methods for using them in treating cell proliferation disorders. He has 1 patent to his name.

Career Highlights

Marc Lafrance is associated with Novartis AG, a leading global healthcare company. His role at Novartis has allowed him to contribute to groundbreaking research and development in the pharmaceutical industry. His innovative approach and dedication to improving patient outcomes have made him a valuable asset to the company.

Collaborations

Throughout his career, Marc has collaborated with esteemed colleagues, including Paul Andrew Barsanti and Sylvie Chamoin. These collaborations have fostered a productive environment for innovation and have led to advancements in their shared field of expertise.

Conclusion

Marc Lafrance's contributions to the field of pharmaceuticals, particularly through his patent on cell proliferation inhibitors, highlight his commitment to advancing medical science. His work at Novartis AG and collaborations with other professionals further emphasize his role as an influential inventor in the industry.